Your browser doesn't support javascript.
loading
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.
Jeong, Hyehyun; Hong, Yong Sang; Kim, Jeong Eun; Lim, Hyeong-Seok; Ahn, Joong Bae; Shin, Sang Joon; Park, Young Suk; Kim, Seung Tae; Han, Sae-Won; Kim, Tae-You; Kim, Tae Won.
Afiliación
  • Jeong H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Seoul, Republic of Korea.
  • Hong YS; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Seoul, Republic of Korea.
  • Kim JE; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Seoul, Republic of Korea.
  • Lim HS; Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Ahn JB; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Shin SJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Han SW; Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Kim TY; Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Seoul, Republic of Korea. twkimmd@amc.seoul.kr.
Invest New Drugs ; 39(5): 1335-1347, 2021 10.
Article en En | MEDLINE | ID: mdl-33829355
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Valina / Benzofenonas / Neoplasias Colorrectales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Valina / Benzofenonas / Neoplasias Colorrectales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2021 Tipo del documento: Article